Advertisement

Patterns of Medical Care Cost by Service Type for Patients With Recurrent and De Novo Advanced Cancer

Published:September 20, 2021DOI:https://doi.org/10.1016/j.jval.2021.06.016

      Highlights

      • Understanding cost patterns for patients with advanced cancer is valuable for assessing the economic burden of disease and program planning and as inputs in cost-effectiveness, simulation studies and payment models that rely on empirical data.
      • Findings from our study of 7112 patients who received a diagnosis of de novo stage IV and recurrent breast, colorectal, and lung cancer between 2000 and 2012 provide new insight into the heterogeneity in direct medical costs, underscoring distinct cost patterns for patients receiving diagnosis of a recurrence <1 year after their initial cancer diagnosis compared with those with a recurrence in 1 year or longer after initial diagnosis and those with de novo stage IV disease.
      • Estimates of medical care costs among patients with advanced cancer that do not account for recurrence and timing of recurrence compared with initial diagnosis may not reflect the true variation in resources required to care for these patients.

      Abstract

      Objectives

      There is limited knowledge about the cost patterns of patients who receive a diagnosis of de novo and recurrent advanced cancers in the United States.

      Methods

      Data on patients who received a diagnosis of de novo stage IV or recurrent breast, colorectal, or lung cancer between 2000 and 2012 from 3 integrated health systems were used to estimate average annual costs for total, ambulatory, inpatient, medication, and other services during (1) 12 months preceding de novo or recurrent diagnosis (preindex) and (2) diagnosis month through 11 months after (postindex), from the payer perspective. Generalized linear regression models estimated costs adjusting for patient and clinical factors.

      Results

      Patients who developed a recurrence <1 year after their initial cancer diagnosis had significantly higher total costs in the preindex period than those with recurrence ≥1 year after initial diagnosis and those with de novo stage IV disease across all cancers (all P < .05). Patients with de novo stage IV breast and colorectal cancer had significantly higher total costs in the postindex period than patients with cancer recurrent in <1 year and ≥1 year (all P < .05), respectively. Patients in de novo stage IV and those with recurrence in ≥1 year experienced significantly higher postindex costs than the preindex period (all P < .001).

      Conclusions

      Our findings reveal distinct cost patterns between patients with de novo stage IV, recurrent <1-year, and recurrent ≥1-year cancer, suggesting unique care trajectories that may influence resource use and planning. Future cost studies among patients with advanced cancer should account for de novo versus recurrent diagnoses and timing of recurrence to obtain estimates that accurately reflect these care pattern complexities.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Value in Health
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mariotto A.B.
        • Enewold L.
        • Zhao J.
        • Zeruto C.A.
        • Yabroff K.R.
        Medical care costs associated with cancer survivorship in the United States.
        Cancer Epidemiol Biomarkers Prev. 2020; 29: 1304-1312
        • Salas-Vega S.
        • Shearer E.
        • Mossialos E.
        Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US.
        Soc Sci Med. 2020; 258: 113042
        • Dolgin E.
        Bringing down the cost of cancer treatment.
        Nature. 2018; 555: S26-S29
      1. Cancer facts figures 2020. American Cancer Society.
        (Accessed September 2019)
        • Harmon W.A.
        Report of the Council on Medical Service - improving risk adjustment in alternative payment models. Council on Medical Service.
        (Accessed August 2019)
        • Lipscomb J.
        • Yabroff K.R.
        • Hornbrook M.C.
        • et al.
        Comparing cancer care, outcomes, and costs across health systems: charting the course.
        J Natl Cancer Inst Monogr. 2013; 2013: 124-130
        • Mariotto A.B.
        • Warren J.L.
        • Zeruto C.
        • et al.
        Cancer-attributable medical costs for colorectal cancer patients by phases of care: what is the effect of a prior cancer history?.
        J Natl Cancer Inst Monogr. 2020; 2020: 22-30
        • Mariotto A.B.
        • Yabroff K.R.
        • Shao Y.
        • Feuer E.J.
        • Brown M.L.
        Projections of the cost of cancer care in the United States: 2010-2020 [published correction appears in J Natl Cancer Inst. 2011;103(8):699].
        J Natl Cancer Inst. 2011; 103: 117-128
        • Shih T.
        • Chen L.M.
        • Nallamothu B.K.
        Will bundled payments change health care? Examining the evidence thus far in cardiovascular care.
        Circulation. 2015; 131: 2151-2158
        • Hassett M.J.
        • Banegas M.
        • Uno H.
        • et al.
        Spending for advanced cancer diagnoses: comparing recurrent versus de novo stage IV disease.
        J Oncol Pract. 2019; 15: e616-e627
        • Ritzwoller D.P.
        • Fishman P.A.
        • Banegas M.P.
        • et al.
        Medical Care costs for recurrent versus de novo stage IV cancer by age at diagnosis.
        Health Serv Res. 2018; 53: 5106-5128
        • Ross T.R.
        • Ng D.
        • Brown J.S.
        • et al.
        The HMO research network virtual data warehouse: a public data model to support collaboration.
        EGEMS (Wash DC). 2014; 2: 1049
      2. Data standards and data dictionary, volume II: version 21. North American Association of Central Cancer Registries.
        • Ritzwoller D.P.
        • Carroll N.
        • Delate T.
        • et al.
        Validation of electronic data on chemotherapy and hormone therapy use in HMOs.
        Med Care. 2013; 51: e67-e73
        • Ritzwoller D.P.
        • Carroll N.M.
        • Delate T.
        • et al.
        Comparative effectiveness of adjunctive bevacizumab for advanced lung cancer: the cancer research network experience.
        J Thorac Oncol. 2014; 9: 692-701
        • Banegas M.P.
        • Yabroff K.R.
        • O’Keeffe-Rosetti M.C.
        • et al.
        Medical care costs associated with cancer in integrated delivery systems.
        J Natl Compr Canc Netw. 2018; 16: 402-410
        • Hassett M.J.
        • Uno H.
        • Cronin A.M.
        • Carroll N.M.
        • Hornbrook M.C.
        • Ritzwoller D.
        Detecting lung and colorectal cancer recurrence using structured clinical/administrative data to enable outcomes research and population health management.
        Med Care. 2017; 55: e88-e98
        • Hassett M.J.
        • Ritzwoller D.P.
        • Taback N.
        • et al.
        Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts.
        Med Care. 2014; 52: e65-e73
        • Hornbrook M.C.
        • Hart G.
        • Ellis J.L.
        • et al.
        Building a virtual cancer research organization.
        J Natl Cancer Inst Monogr. 2005; : 12-25
        • O’Keeffe-Rosetti M.C.
        • Hornbrook M.C.
        • Fishman P.A.
        • et al.
        A standardized relative resource cost model for medical care: application to cancer control programs.
        J Natl Cancer Inst Monogr. 2013; 2013: 106-116
        • Basu A.
        • Manning W.G.
        Estimating lifetime or episode-of-illness costs under censoring [published correction appears in Health Econ. 2011;20(1):125-126].
        Health Econ. 2010; 19: 1010-1028
        • Guy Jr., G.P.
        • Ekwueme D.U.
        • Yabroff K.R.
        • et al.
        Economic burden of cancer survivorship among adults in the United States.
        J Clin Oncol. 2013; 31: 3749-3757
        • Manning W.G.
        • Basu A.
        • Mullahy J.
        Generalized modeling approaches to risk adjustment of skewed outcomes data.
        J Health Econ. 2005; 24: 465-488
        • Deb P.
        • Norton E.C.
        Modeling health care expenditures and use.
        Annu Rev Public Health. 2018; 39: 489-505
        • Jones A.M.
        Models for health care.
        in: Clements M.P. Hendry D.F. The Oxford Handbook of Economic Forecasting. Oxford University Press, Oxford, United Kingdom2011
        • Manning W.G.
        • Mullahy J.
        Estimating log models: to transform or not to transform?.
        J Health Econ. 2001; 20: 461-494
        • Quan H.
        • Sundararajan V.
        • Halfon P.
        • et al.
        Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.
        Med Care. 2005; 43: 1130-1139
        • Blough D.K.
        • Ramsey S.D.
        Using generalized linear models to assess medical care costs.
        Health Serv Outcomes Res Methodol. 2000; 1: 185-202
        • Ramsey S.D.
        • Newton K.
        • Blough D.
        • et al.
        Incidence, outcomes, and cost of foot ulcers in patients with diabetes.
        Diabetes Care. 1999; 22: 382-387
        • Chang C.F.
        • Gould M.
        Playing the odds: lung cancer surveillance after curative surgery.
        Curr Opin Pulm Med. 2017; 23: 298-304
        • Weeks J.C.
        • Catalano P.J.
        • Cronin A.
        • et al.
        Patients’ expectations about effects of chemotherapy for advanced cancer.
        N Engl J Med. 2012; 367: 1616-1625
        • Newcomer L.N.
        Innovative payment models and measurement for cancer therapy.
        J Oncol Pract. 2014; 10: 187-189
        • Aviki E.M.
        • Schleicher S.M.
        • Mullangi S.
        • Matsoukas K.
        • Korenstein D.
        Alternative payment and care-delivery models in oncology: a systematic review.
        Cancer. 2018; 124: 3293-3306
        • Guas C.
        • Pittman D.
        Evaluation of Medicare alternative payment models: what the data show. HealthAffairs.
        (Accessed November 2020)
        • Basch E.
        Evaluating alternative payment models in oncology.
        JAMA. 2017; 317: 2123-2124
        • Kline R.M.
        • Muldoon L.D.
        • Schumacher H.K.
        • et al.
        Design challenges of an episode-based payment model in oncology: the Centers for Medicare & Medicaid Services oncology care model.
        J Oncol Pract. 2017; 13: e632-e645
        • Sagar B.
        • Lin Y.S.
        • Castel L.D.
        Cost drivers for breast, lung, and colorectal cancer care in a commercially insured population over a 6-month episode: an economic analysis from a health plan perspective.
        J Med Econ. 2017; 20: 1018-1023
        • Patel K.
        • Thoumi A.
        • Nadel J.
        • O’Shea J.
        • McClellan M.
        Transforming oncology care: payment and delivery reform for person-centered care.
        Am J Manag Care. 2015; 21: 388-393
        • Farjah F.
        • Monsell S.E.
        • Gould M.K.
        • et al.
        Association of the intensity of diagnostic evaluation with outcomes in incidentally detected lung nodules.
        JAMA Intern Med. 2021; 181: 480-489